Idorsia Ltd (IDRSF)

Market Cap	967.77M +263.3%
Revenue (ttm)	278.18M +96.1%
Net Income	-140.86M
EPS	-0.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	7,379
Open	4.030
Previous Close	n/a
Day's Range	4.030 - 4.030
52-Week Range	1.000 - 5.820
Beta	1.75
RSI	47.82
Earnings Date	Apr 28, 2026

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDRSF

Financial Performance

In 2025, Idorsia's revenue was 220.58 million, an increase of 96.06% compared to the previous year's 112.51 million. Losses were -111.70 million, -57.65% less than in 2024.

Financial numbers in CHF